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The Yaa Mutation Promoting Murine Lupus Causes Defective
Development of Marginal Zone B Cells1
Hirofumi Amano, 2* Eri Amano, 2* Thomas Moll,* Dragan Marinkovic, † Nabila Ibnou-Zekri,*
Eduardo Martinez-Sorı́a,* Isabelle Semac,* Thomas Wirth,† Lars Nitschke,‡ and Shozo Izui3*
The accelerated development of systemic lupus erythematosus (SLE) in BXSB male mice is associated with the presence of an as
yet unidentified mutant gene,Yaa (Y-linked autoimmune acceleration). In view of a possible role of marginal zone (MZ) B cells
in murine SLE, we have explored whether the expression of theYaa mutation affects the differentiation of MZ and follicular B
cells, thereby implicating the acceleration of the disease. In this study, we show that both BXSB and C57BL/6Yaa mice, including
two different substrains of BXSB Yaa males that are protected from SLE, displayed an impaired development of MZ B cells early
in life. Studies in bone marrow chimeras revealed that the loss of MZ B cells resulted from a defect intrinsic to B cells expressing
the Yaa mutation. The lack of selective expansion of MZ B cells in diseased BXSBYaa males strongly argues against a major role
of MZ B cells in the generation of pathogenic autoantibodies in the BXSB model of SLE. Furthermore, a comparative analysis with
mice deficient in CD22 or expressing an IgM anti-trinitrophenyl/DNA transgene suggests that the hyperreactive phenotype ofYaa
B cells, as judged by a markedly increased spontaneous IgM secretion, is likely to contribute to the enhanced maturation toward
follicular B cells and the block in the MZ B cell generation. The Journal of Immunology, 2003, 170: 2293–2301.
T he BXSB strain of mice spontaneously develops an auto-immune syndrome with features of systemic lupus ery-thematosus (SLE)4 that affects males much earlier than
females (1). This accelerated development of SLE in male BXSB
mice is due to the presence of an as yet unidentified mutant gene
located on the Y chromosome, designated Yaa (Y-linked autoim-
mune acceleration) (2). The Yaa gene by itself is unable to induce
significant autoimmune responses in mice without an apparent
SLE background, while it can induce and accelerate the develop-
ment of SLE in combination with autosomal susceptibility alleles
present in lupus-prone mice (3, 4). The selective production of
anti-DNA autoantibodies by B cells bearing the Yaa gene in Yaa
and non-Yaa double bone marrow chimeric mice revealed that the
Yaa defect is expressed in B cells (5, 6). Based on these results, it
can be speculated that the Yaa defect may decrease the threshold
for B cell Ag receptor (BCR)-mediated signaling, thereby trigger-
ing and excessively stimulating autoreactive B cells (7).
Newly generated B cells in the bone marrow emigrate to the
spleen, in which two types of transitional mature B cell precursors
(T1 and T2) exist (8). In the spleen, immature transitional B cells
can further differentiate into follicular or marginal zone (MZ) B
cells, which differ in their localization and cell surface markers.
Follicular, recirculating B cells are IgMintIgDhighCD21intCD23high
CD1lowCD9low, and resident MZ B cells located at the junction of
white and red pulps are IgMhighIgDlowCD21highCD23neg/lowCD1high
CD9high (9–11). Although follicular B cells respond to T-dependent
Ags, MZ B cells have recently been proposed to play a critical role in
host defense against T-independent blood-borne pathogens (12, 13).
In addition, several recent studies have claimed a potential role for
MZ B cells in the spontaneous development of autoantibodies in sys-
temic autoimmunity. CD1high B cells have been reported to produce
large amounts of IgM anti-DNA Abs in lupus-prone (NZB 
NZW)F1 mice (14), which apparently have an increased number of
MZ B cells (15). In addition, it has been shown that mice overex-
pressing B cell-activating factor of the TNF family (BAFF) sponta-
neously develop an SLE-like syndrome in association with a marked
increase in T2 and MZ B cells (16, 17). Because BAFF is apparently
a potent survival factor for immature T2 B cells, it can be speculated
that autoreactive T2 B cells could escape deletion and differentiate
into autoreactive MZ B cells in these mice. This is consistent with the
findings that autoreactive B cells are accumulated in the MZ (18, 19).
However, it still remains to be established that MZ B cells indeed
secrete pathogenic autoantibodies implicated in SLE.
Molecular mechanisms regulating the differentiation into MZ vs
follicular B cells have not been fully defined. However, studies on
several different genetically manipulated mice have suggested that
the impaired development of MZ B cells could be related to de-
fects in chemotactic migration to the MZ (20–22) and to hyper-
sensitive BCR signaling, favoring an accelerated maturation to-
ward follicular B cells (23–26). The latter hypothesis has further
been supported by the demonstration that the specificity and sur-
face density of BCR are the critical factors determining the lineage
commitment to different B cell subsets (27, 28). Because the Yaa
mutation may act by enhancing BCR signaling, it could bring
along a reduction of MZ B cell development. Alternatively, if the
accelerated development of SLE by the Yaa gene is associated
with an increased production of pathogenic autoantibodies by MZ
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B cells, the number of MZ B cells may rather be increased in mice
bearing the Yaa mutation. We show in this study that the devel-
opment of MZ B cells is markedly diminished in the presence of
the Yaa mutation and not expanded during the course of SLE in
BXSB mice, and discuss the possible mechanisms by which the
Yaa mutation leads to the MZ B cell defect and autoimmunity.
Materials and Methods
Mice
BXSB mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). BXSB (H-2b) male, but not female mice develop an accelerated SLE,
which results in part from the action of the Yaa gene (1), and do not express
MHC class II I-E molecules because of a defect in the Ea gene encoding
the I-E -chain (29). BXSB mice lacking the Yaa gene or bearing the H-2d
haplotype (BXSB.H-2d), or an Ea transgene (BXSB.E), and C57BL/6
(B6) mice bearing the Yaa mutation have been previously described (4,
29–31). The B6.C20 strain carrying the IgHa allotype, instead of the IgHb
allotype, on the B6 background was kindly provided by M. Bosma (Phil-
adelphia, PA). CD22/ mice with a pure B6 background were developed
as described previously (32). BXSB mice expressing an Sp6 anti-
trinitrophenyl (TNP)/DNA IgM transgene (33) were created by backcross
procedures at the eighth generation. The analysis of transgenic IgMa and
endogenous IgMb expression in Sp6 transgenic mice showed that the ma-
jority (90%) of splenic B cells expressed the transgene.
Preparation of bone marrow chimeras
Three- to 4-mo-old BXSB.E Yaa or non-Yaa male recipients (I-E) were
irradiated at 850 rad and reconstituted with 5  106 bone marrow cells
from 3- to 4-mo-old BXSB Yaa or non-Yaa male donors (I-E), as de-
scribed previously (5). Two months later, chimerism in recipients was con-
trolled by the absence of I-E-positive circulating B cells by flow cytomeric
analysis. In some experiments, a mixture of donor bone marrow cells from
Yaa B6 male mice bearing the IgHb allotype and non-Yaa B6.C20 male
mice bearing the IgHa allotype was injected into irradiated B6 male mice.
As control, a mixture of bone marrow cells from IgHa and IgHb non-Yaa
male mice was injected into irradiated B6 male mice. Chimerism in recip-
ients was controlled by the presence of IgMa and IgMb allotype-positive
circulating B cells 2 mo after the reconstitution.
Flow cytometric analysis
Flow cytometry was performed using two- or three-color staining of spleen
cells, and analyzed with a FACSCalibur (BD Biosciences, Mountain View,
CA). The following Abs were used: anti-CD21 (7G6), anti-CD23 (B3B4),
anti-CD22 (CY34), anti-CD19 (1D3), anti-B220 (RA3-6B2), anti-IgMa
(RS-3.1), anti-IgMb (MB86), anti-IgD (AF6-122), anti-CD1d (1B1), anti-
CD9 (KMC8), anti-I-A (Y-3P), anti-I-E (Y-17), anti-LFA-1 -chain
(CD11a; H35.89.9), and anti-1 integrin (CD29; Ha2/5) mAb, and poly-
clonal goat anti-human IgG (BD PharMingen, San Diego, CA). Human
BAFF-human IgG Fc (BAFF-Fc) fusion protein was a kind gift of J.
Tschopp (Lausanne, Switzerland). Staining was performed in the presence
of saturating concentration of 2.4G2 anti-FcRII/III mAb.
Immunohistochemistry
Spleens from 2-mo-old BXSB mice of both Yaa and non-Yaa genotypes
were embedded in Tissue-Tek OCT compound and snap frozen in liquid
nitrogen. Frozen sections (4 m) were stained with PE-labeled anti-IgM
(1B4B1; Southern Biotechnology, Birmingham, AL), FITC-labeled anti-
IgD (11-26c.2a; PharMingen), and FITC-labeled MOMA-1 (Serotec, Ox-
ford, U.K.) mAb in the presence of 2.4G2 anti-FcRII/III mAb, as de-
scribed previously (26).
Immunizations and ELISA
Two-month-old B6 Yaa and non-Yaa male mice were immunized i.v. with
50 g of thymus-independent type 2 (TI-2) Ag, NIP-Ficoll (Biosearch
Technologies, San Francisco, CA), and bled on days 0 and 7. Serum levels
of IgM and IgG3 anti-(4-hydroxy-3-iodo-5-nitrophenyl)acetyl (NIP) Abs
were determined by ELISA, using alkaline phosphatase-labeled rat anti-
mouse IgM (LO-MM-9) and anti-mouse IgG3 (H139.61.1) mAb. Results
are expressed as U/ml in reference to a standard curve established by using
a pooled sera from B6 mice immunized with NIP-Ficoll. In addition, IgM
concentrations in culture supernatants were determined by IgM-specific
ELISA, as described previously (34).
Purification of splenic B cells and cell culture
B cells were purified from spleen by adherence of macrophages for 1 h at
37°C on plastic plates and subsequent treatment with IgM anti-Thy-1.2
(AT-83) mAb in the presence of rabbit complement (Cedarlane, Ontario,
Canada). The purity of B cells, as documented by flow cytometric analysis,
was superior to 95%. For spontaneous IgM secretion, 5  105 splenic B
cells purified from Yaa and non-Yaa B6 male mice were incubated in 0.2
ml of DMEM containing 10% FCS at 37°C for 24 h. For proliferative
responses of splenic B cells, 2  105 spleen cells were incubated with 1,
5, or 25 g/ml of B7-6 anti-IgM mAb in 0.2 ml of DMEM-10% FCS at
37°C, and cultures were pulsed with [3H]thymidine for the final 6 h of 3
days’ culture.
Western blot analysis
Total lysates of purified splenic B cells from 2-mo-old BXSB and B6 mice
of the Yaa and non-Yaa genotypes (three mice for each group) were sep-
arated on a 10% minigel and transferred to nitrocellulose (Hybond-C; Am-
ersham Pharmacia Biotech, Dübendorf, Switzerland) with a semidry blot-
ting apparatus (Bio-Rad, Glattbrugg, Switzerland). After 2 h of blocking at
room temperature in TTBS (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, and
0.05% Tween 20) containing 5% low-fat, dry milk powder (TTBS-MP),
the filters were incubated with polyclonal rabbit anti-Lyn (amino-terminal)
Abs (Santa Cruz Biotechnology, Heidelberg, Germany) in TTBS-MP over-
night at 4°C. Thoroughly washed filters were incubated with alkaline-phos-
phatase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology) for
1 h at room temperature. Chemiluminescence development was conducted
with the Immun-Star Pack reagents (Bio-Rad), and the filters were exposed
to X-OMAT Kodak films.
RT-PCR
Five micrograms of total RNA were prepared from purified splenic B cells
of 2-mo-old BXSB and B6 mice of both Yaa and non-Yaa genotype (three
mice for each group) by RNeasy Mini kit (Qiagen AG, Basel, Switzerland).
The first strand of cDNA (20 l) was synthesized with an oligo(dT) primer
and total RNA. For amplification with Taq DNA polymerase (Roche,
Basel, Switzerland), the following primers for Aiolos and SHP-1 genes
were used: Aiolos forward primer (5-GGCATCTTTTACTCAGAAAGG)
and reverse primer (5-TGGCTTGGTCCATCATCCG), and SHP-1 for-
ward primer (5-CCTGGACATTTCTTGTGCG) and reverse primer (5-
GTTCTCATCTGGACCTAGC). PCR products obtained following ampli-
fication of 5 l of cDNA diluted 1/50, 1/250, and 1/1250 were visualized
after electrophoresis through 2% agarose gels by staining with ethidium
bromide. The PCR products obtained with optimal cDNA concentration,
which gave an exponential phase of amplification, were quantified by den-
sitometric analysis. A reference control gene (GAPDH) was also amplified
with forward primer (5-TGAAGGTCGGTGTGAACGGATTTGG) and
reverse primer (5-ACGACATACTCAGCACCAGCATCAC) to standard-
ize amounts of RNA and to allow calculation of relative amounts of gene
expression. To ensure the absence of sample contamination, a reaction
mixture with no added cDNA was run in parallel with each PCR.
Measurement of intracellular Ca2 mobilization
A total of 107 spleen cells from B6 Yaa and non-Yaa male mice was loaded
with 4.5 M Indo-1 (Molecular Probes, Eugene, OR) and 0.04% pluronic
F-127 in RPMI (pH 7.4) with 1% FCS for 45 min at 37°C. After Indo-1
loading, cells were stained on ice with FITC-labeled anti-B220 mAb. Cells
were washed, and IgM on the B cell surface was cross-linked at 37°C with
10, 30, or 90 g/ml of B7-6 anti-IgM mAb. Increases of intracellular Ca2
in splenic B220 B cells were recorded in real time for 6 min with a
FACSVantage (BD Biosciences). The anti-B220 staining had no effect on
Ca2 flux, as was checked by comparison with unstained B cells.
Statistical analysis
Statistical analysis was performed with the Wilcoxon two-sample test. Val-
ues of p  5% were considered insignificant.
Results
Reduction of MZ B cells in BXSB and B6 mice bearing the Yaa
mutation
To investigate whether the Yaa mutation affected the size of the
MZ B cell compartment, flow cytometric analysis of spleen cells
from lupus-prone BXSB mice at 2 mo of age was performed. Anal-
ysis of cell surface expression of CD21 and CD23 on B220-pos-
itive population defines immature T1 B cells (CD21negCD23neg),
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follicular B cells (CD21intCD23high), and MZ B cells (CD21high
CD23neg/low). When compared with BXSB males or females lack-
ing the Yaa mutation, MZ B cells were substantially (4-fold)
diminished in BXSB Yaa male mice (Fig. 1, A and C). This phe-
notypic defect was further confirmed with the use of other markers,
including CD1d and CD9 (Fig. 1B). Histologically, spleens from
BXSB Yaa male mice showed normal anatomical structures. The
resident metallophilic, MOMA-1 MZ macrophages were cor-
rectly localized. However, in agreement with the flow cytometric
analysis, a characteristic rim of IgMIgD MZ B cells at the pe-
riphery of the follicles and separated by MOMA-1 macrophages
was poorly visible in the spleens of BXSB Yaa males, as compared
with non-Yaa BXSB males (Fig. 2).
The observed reduction of MZ B cells in BXSB Yaa male mice
could be secondary to the accelerated development of autoimmune
responses occurring in these mice, rather than a direct effect of the
Yaa gene defect on MZ B cell generation. To exclude this possi-
bility, we determined the size of the MZ B cell compartment in two
different substrains of BXSB male mice (BXSB.H-2d and
BXSB.E). These two substrains of BXSB male mice carry the
Yaa mutation, but fail to develop SLE during the first year of life,
because of the presence of the H-2d haplotype (30) or the transgene
encoding an I-E -chain (29), respectively. Despite the absence of
significant autoantibody production, the development of the
CD21highCD23neg/low MZ B cell compartment in these two BXSB
substrains was markedly limited, and indistinguishable from that
of conventional BXSB Yaa male mice (Fig. 1, A and C). The
association of the MZ B cell defect with the Yaa mutation was
further confirmed by analysis in 2-mo-old B6 Yaa male mice (Fig.
1, A and C), which lack significant autoantibody production. More
significantly, 6- to 8-mo-old conventional BXSB Yaa male mice
developing severe SLE did not shown any sign of selective ex-
pansion of MZ B cells (Fig. 1, A and C), arguing against a major
role of MZ B cells in the production of pathogenic lupus autoan-
tibodies in the BXSB model of SLE. Although we noted a slight
reduction of MZ B cells in 8-mo-old BXSB non-Yaa males, dif-
ferences between Yaa and non-Yaa males were still highly signif-
icant (data not shown).
Reduction of MZ B cells due to an intrinsic defect of B cells
expressing the Yaa mutation
To determine whether the impaired MZ B cell development in
mice bearing the Yaa mutation resulted from a defect in B cells
themselves or in the stromal microenvironment that supports the
FIGURE 1. Reduction of MZ B cells in BXSB and B6 mice bearing the
Yaa mutation. A, Spleen cells from BXSB, BXSB.E, and B6 male mice
of the Yaa or non-Yaa genotype at 2 and 8 mo of age were stained with a
combination of anti-B220, anti-CD21, and anti-CD23 mAb, and gated for
B220 cells. Mean percentages of MZ B cells (CD21highCD23neg/low) in
total spleen are indicated. Representative results from 8–20 mice in each
group are shown. B, Spleen cells from 2-mo-old BXSB mice were stained
with anti-CD21 and anti-CD1d mAb or with a combination of anti-IgM,
anti-IgD, and anti-CD9 mAb. Percentages of MZ B cells (CD21high
CD1dhigh) are indicated. Histograms show CD9 staining of the IgMhigh
IgDlow population of B cells enriched in MZ B cells. Percentages of
CD9high cells in the IgMhighIgDlow B cell population are indicated. Repre-
sentative results from five to seven mice are shown. C, Percentages of MZ
B cells (CD21highCD23neg/low) in spleen from BXSB, BXSB.H-2d,
BXSB.E, and B6 male mice of the Yaa or non-Yaa genotype at 2 and 6–8
mo of age. Means (SD) of each group are: 2-mo-old BXSB Yaa, 1.3 
0.8%; 6- to 8-mo-old BXSB Yaa, 0.8  0.4%; 2-mo-old BXSB.H-2d Yaa,
1.0  0.5%; 2-mo-old BXSB.E Yaa, 0.9  0.7%; 2-mo-old BXSB non-
Yaa, 4.7  0.7%; 2-mo-old B6 Yaa, 1.2  0.4%; 2-mo-old B6 non-Yaa,
4.8  1.1%. The results obtained with BXSB female mice were essentially
identical with those of non-Yaa BXSB male mice (means of 5 mice  SD:
4.8  1.0%).
FIGURE 2. Reduction of the MZ B cell compartment in BXSB Yaa
male mice. Spleen sections from 2-mo-old BXSB Yaa and non-Yaa male
mice were stained with PE-labeled anti-IgM (red) and FITC-labeled anti-
MOMA-1 (green) (A, Yaa and B, Non-Yaa) or PE-labeled anti-IgM (red)
and FITC-labeled anti-IgD (green) mAb (C, Yaa and D, Non-Yaa). Rep-
resentative results obtained from four mice in each group are shown.
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development of MZ B cells, we performed reciprocal bone marrow
cell reconstitution experiments between BXSB Yaa and non-Yaa
male mice. The transfer of bone marrow cells from BXSB non-Yaa
males into irradiated BXSB Yaa males efficiently reconstituted MZ
B cells (means of 7 mice  SD: 4.4  0.5%), as documented by
flow cytometric analysis (Fig. 3A). The extent of the MZ B cell
development observed in these mice was comparable to that ob-
served in non-Yaa mice reconstituted with non-Yaa bone marrow
cells (means of 4 mice  SD: 4.6  1.1%). In contrast, MZ B cells
were poorly developed in irradiated BXSB non-Yaa males recon-
stituted with bone marrow cells from BXSB Yaa males (means of
5 mice  SD: 1.4  0.3%).
To confirm that the impaired development of MZ B cells in Yaa
mice resulted from a defect intrinsic to B cells bearing the Yaa
mutation, the development of MZ B cells was assessed in irradi-
ated B6 male mice reconstituted with a mixture of bone marrow
cells from Yaa B6 (IgHb) and non-Yaa B6.C20 (IgHa) male mice.
As control, irradiated B6 male mice were reconstituted with bone
marrow cells from both non-Yaa B6 and B6.C20 male mice. The
analysis of surface IgM allotypes revealed a selective accumula-
tion of IgMa-positive B cells of non-Yaa origin in the MZ, but not
in the follicular B cell compartment of Yaa/non-Yaa mixed chi-
meras, which contrasted with the comparable localization of B
cells bearing either IgM allotype in control chimeras (Fig. 3B).
Notably, the size of the MZ B cell compartment was somehow
lower in Yaa/non-Yaa mixed chimeras (means of 4 mice  SD:
3.3  1.5%) than that in control chimeras (means of 3 mice  SD:
4.7  0.9%), most likely due to the defective development of MZ
B cells of Yaa origin.
Reduction of T2 B cells in BXSB and B6 mice bearing the Yaa
mutation
It has been considered that T2 B cells are the immediate precursors
differentiating into either MZ or follicular B cells (17, 24). Therefore,
the distribution of immature T1 (CD21negCD23negIgMhighIgDneg)
and T2 (CD21highCD23highIgMhighIgDhigh) B cells (8) was examined
in 2-mo-old BXSB and B6 male mice in relation to the Yaa mutation.
The proportion of newly formed T1 B cells appeared almost compa-
rable in both Yaa and non-Yaa males of either strain, while the size of
the T2 B cell compartment was substantially diminished in both
BXSB and B6 Yaa males (Fig. 4A), suggesting an accelerated matu-
ration of T2 B cells toward follicular B cells in Yaa male mice. No-
tably, a more pronounced decrease of T2 B cells than T1 B cells was
similarly observed in B6 mice deficient in the negative BCR regulator
CD22 (data not shown), which are also defective in the generation of
MZ B cells (26).
FIGURE 3. Impaired development of MZ B cells of Yaa origin in bone
marrow radiation chimeras. A, Irradiated Yaa or non-Yaa BXSB male mice
were reconstituted with bone marrow cells from BXSB Yaa or non-Yaa
males. Two months after reconstitution, spleen cells were stained with a
combination of anti-B220, anti-CD21, and anti-CD23 mAb, and gated for
B220 cells. Mean percentages of MZ B cells (CD21highCD23neg/low) in
spleen are indicated. Representative results from five to seven mice in each
group (Yaa3Non-Yaa and Non-Yaa3Yaa) are shown. B, Irradiated B6
mice were reconstituted with a mixture of bone marrow cells from Yaa B6
(IgHb) and non-Yaa B6.C20 (IgHa) male mice (Yaa  Non-Yaa) or from
non-Yaa B6 and B6.C20 male mice (control chimera). Two months after
reconstitution, spleen cells were stained with a combination of anti-CD21,
anti-CD23, and anti-IgM mAb. Histograms show non-Yaa-derived IgMa
staining of MZ (CD21highCD23neg/low) and follicular (FO; CD21intCD23high)
B cells in both mixed chimeras, and mean percentages (SD) of IgMa-positive
B cells in each compartment from three to four mice of each group are indi-
cated. Note a selective accumulation of IgMa-positive B cells of non-Yaa or-
igin in the MZ of Yaa/non-Yaa mixed chimeras. This was confirmed by IgMb
staining of Yaa B cells (data not shown).
FIGURE 4. Reduction of T2 B cells in 2-mo-old BXSB Yaa mice. A,
Spleen cells were stained with a combination of anti-IgM, anti-IgD, and
anti-CD21 mAb, in which percentages of T1 (CD21negIgMhigh) and T2
(IgMhighIgDhigh) B cells are indicated. B, Spleen cells were stained with a
combination of anti-IgM, anti-CD21, and anti-CD23 mAb. Within the
CD23 and CD23 cell gates, percentages of MZ (IgMhighCD21high
CD23–), T1 (IgMhighCD21negCD23), and T2 (IgMhighCD21highCD23) B
cells are indicated. Essentially identical results were obtained with B6 Yaa
male and CD22/ mice (data not shown). Representative results from
three to five mice are shown.
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It has been shown that BAFF secreted by dendritic cells, mono-
cytes/macrophages, and T cells (16, 35, 36) is apparently a potent
survival factor for T2 B cells, as overexpression of BAFF led to a
remarkable expansion of the T2 B cell population, accompanied by
an increase in MZ B cells (17). Thus, the reduction of T2 and MZ
B cells in Yaa male mice could be related to a lower expression of
BAFF-binding receptors. However, this possibility was excluded,
because the flow cytometric analysis using BAFF-Fc did not show
any significant differences in the binding of BAFF-Fc on T2, MZ,
and follicular B cells from Yaa and non-Yaa BXSB and B6 males
(data not shown).
A more recent study has demonstrated that an up-regulated ex-
pression of integrins, LFA-1 (L2) and 41, on MZ B cells and
the interaction with their respective ligands, ICAM-1 and
VCAM-1, expressed on resident stromal cells in the MZ is critical
for the localization and retention of MZ B cells (37). Staining with
anti-LFA-1 -chain (L) and anti-1 integrin mAb confirmed
higher levels of these two integrins in MZ B cells than in follicular
B cells in non-Yaa B6 male mice (Fig. 5). However, we did not
find any significant differences in the level of surface staining by
anti-L and anti-1 mAb on MZ and follicular B cells between Yaa
and non-Yaa mice. In addition, flow cytometric analysis failed to
show the appearance of the MZ-phenotype B cells in the peripheral
blood of Yaa mice, as opposed to mice treated with anti-L and
anti-4 mAb, causing the displacement of MZ B cells into the
blood (37).
Decreased levels of CD21 expression on follicular B cells from
BXSB and B6 mice bearing the Yaa mutation
It has recently been reported that the absence of MZ B cells in
Aiolos/ mice is accompanied by the enhanced maturation of
follicular B cells characterized by a lower level of CD21 expres-
sion (24). This was interpreted as a result of hypersensitive BCR
signaling in Aiolos-deficient B cells, favoring the maturation of T2
B cells toward follicular B cells. In fact, CD22-deficient follicular
B cells, which are hyperresponsive to BCR triggering, also exhib-
ited a down-regulation of CD21 expression (Fig. 6). Because the
Yaa defect may lead to an excessive activation of B cells, possibly
through lowering the threshold for BCR-mediated signaling, we
assessed whether the CD21 expression was similarly altered in
follicular B cells from BXSB or B6 male mice carrying the Yaa
mutation. The intensity of CD21 staining on follicular
CD21intCD23high B cells was significantly reduced in Yaa males,
as compared with non-Yaa males in both strains of mice ( p 
0.005; Fig. 6). Although the differences were relatively small, fol-
licular B cells from Yaa mice consistently showed lower levels of
CD21 in several independent analyses. Notably, we did not find
any measurable differences on splenic B cells between Yaa and
non-Yaa BXSB and B6 male mice in their expression levels of
different BCR coreceptors, CD22, CD19, and FcRIIB, and MHC
class II I-A, as determined by flow cytometric analysis. This was
also the case for Lyn, SHP-1, and Aiolos, all of which are known
to be implicated in BCR signaling and the MZ B cell development,
as assessed by Western blot or semiquantitative RT-PCR analysis
(data not shown).
Increased spontaneous secretion of IgM in Yaa B6 male mice,
but comparable responses to TI-2 Ag between Yaa and non-Yaa
B6 male mice
CD21 down-regulation in follicular B cells bearing the Yaa mu-
tation suggested that these B cells resemble lymphocytes that have
been constitutively activated, as the expression of CD21 is known
to be reduced following BCR-mediated activation of B cells (38,
39). If this is the case, one can expect an increased spontaneous
secretion of IgM Abs by splenic B cells bearing the Yaa mutation.
In fact, when 2-mo-old Yaa and non-Yaa B6 male mice were com-
pared, the amount of IgM spontaneously secreted during a 24-h
culture by splenic B cells bearing the Yaa mutation was 10-fold
higher than that of non-Yaa counterparts (Fig. 7A). However, Yaa
FIGURE 5. Lack of differences in expression levels of L- and 1-con-
taining integrins on MZ and follicular B cells between Yaa and non-Yaa B6
male mice. Spleen cells from 2-mo-old Yaa and non-Yaa B6 males were
stained with a combination of anti-CD21, anti-CD23, and anti-L or anti-
1 mAb. Histograms show L or 1 staining of MZ (CD21
highCD23neg/low)
and follicular (FO; CD21intCD23high) B cells from Yaa and non-Yaa mice.
Mean fluorescence intensities (SD) of L and 1 from five B6 mice of the
Yaa or non-Yaa genotype are indicated.
FIGURE 6. Decreased expression of CD21 in follicular B cells from 2-mo-old CD22/ and Yaa mice. Spleen cells were stained with a combination
of anti-B220, anti-CD21, and anti-CD23 mAb. Within the B220 cell population, CD21intCD23high follicular B cells were gated, with maximal exclusion
of T2 (CD21highCD23high) cells. Histograms show CD21 staining of follicular B cells, in which the presence of contaminating T2 cells was too limited to
influence the value of peak fluorescence intensity of CD21. Mean fluorescence intensities (SD) of CD21 from five BXSB and B6 mice of the Yaa or
non-Yaa genotype and from two CD22/ and wild-type B6 mice are indicated. Differences in the fluorescence intensity of CD21 between Yaa and
CD22/ mice are due to the fact that these analyses were conducted in the laboratory of S. Izui and L. Nitschke, respectively, by using different batches
of mAb.
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B cells did not show any significant differences in Ca2 influx and
proliferative responses following BCR cross-linking with B7-6 anti-
IgM mAb at any dose tested (data not shown).
It has been shown that MZ B cells play a major role in humoral
responses against TI-2 Ags (20). To test whether the reduction of
MZ B cells in B6 Yaa mice affected their immune responses to
TI-2 Ags, 2-mo-old B6 mice were immunized i.v. with NIP-Ficoll.
NIP-specific IgM and IgG3 concentrations in B6 Yaa males during
the response to the TI-2 Ag were comparable to those of non-Yaa
counterparts (Fig. 7B).
Increased development of MZ B cells in BXSB Yaa male mice
expressing an Sp6 IgM anti-TNP/DNA transgene
To further define the possible mechanism responsible for the Yaa-
linked MZ B cell defect, we determined the effect of the Yaa mu-
tation on the development of MZ B cells expressing a transgene
encoding an Sp6 IgM anti-TNP/DNA Ab in BXSB mice. Studies
in several different Ig transgenic mice have shown that the pro-
portion of MZ B cells varies depending on the specificity of BCR,
and that partially autoreactive B cells tend to be more accumulated
in the MZ B cell compartment (19, 40). In agreement with results
obtained in mice expressing a VH81X H chain transgene confer-
ring self-reactivity (40), the flow cytometric analysis revealed that
the proportion of MZ B cells was significantly enlarged in 2-mo-
old non-Yaa BXSB Sp6 transgenic male mice (means of 5 mice 
SD: 9.4  2.1%), as compared with nontransgenic littermates
(means of 4 mice  SD: 4.6  1.3%) (Fig. 8A). In contrast to a
compromised development of MZ B cells in Yaa BXSB nontrans-
genic males (means of 4 mice  SD: 1.1  1.5%), the size of the
MZ B cell compartment in Sp6 transgenic BXSB Yaa males was
markedly increased (means of 5 mice  SD: 7.5  2.4%), reach-
ing a level almost comparable to that of non-Yaa BXSB transgenic
mice. These results suggest that MZ B precursors expressing the
Yaa mutation have the potential to migrate toward the MZ almost
as efficiently as those of non-Yaa origin. Notably, the levels of
CD21 expression on follicular B cells and of spontaneous IgM
secretion by splenic B cells did not significantly differ between Yaa
and non-Yaa Sp6 transgenic male mice (Fig. 8, B and C).
Discussion
In the present study, we have demonstrated that lupus-prone BXSB
and nonautoimmune B6 mice bearing the Yaa mutation display a
defect in the development of MZ B cells, as documented by flow
cytometric or histological analysis. This defect was similarly ob-
served in two BXSB Yaa substrains (BXSB.H-2d and BXSB.E),
which are protected from SLE (29, 30), indicating that the defect
in the MZ B cell generation is directly linked to the Yaa mutation,
and not secondary to the development of lupus-like autoimmune
responses. Studies in bone marrow chimeras revealed that the se-
lective loss of MZ B cells in Yaa mice results from a defect in-
trinsic to B cells expressing the Yaa mutation. In addition, the lack
FIGURE 7. Increased secretion of IgM by splenic B cells from B6 male
mice bearing the Yaa mutation, but comparable Ab responses to TI-2 Ag,
NIP-Ficoll. A, Spontaneous secretion of IgM in vitro after a 24-h incuba-
tion of splenic B cells from 2-mo-old B6 male mice of the Yaa or non-Yaa
genotype was determined by ELISA. IgM concentrations in supernatants
from three different mice (means  SD) are expressed as ng/ml of IgM. B,
Serum levels of IgM and IgG3 anti-NIP Abs were determined by ELISA 7
days after an i.v. injection of 50 g of NIP-Ficoll into 2-mo-old B6 mice.
Results are expressed as units per milliliter of anti-NIP Abs. Serum levels
of IgM and IgG3 anti-NIP Abs before the immunization were 10 and 1
U/ml, respectively, in Yaa and non-Yaa B6 males.
FIGURE 8. Increased MZ B cell development, and lack of CD21 down-
modulation on follicular B cells and of increased spontaneous IgM secre-
tion by splenic B cells in BXSB Yaa male mice expressing an Sp6 IgM
anti-TNP/DNA transgene. A, Spleen cells from 2-mo-old Yaa and non-Yaa
BXSB Sp6 transgenic males and their nontransgenic littermates were
stained with a combination of anti-B220, anti-CD21, and anti-CD23 mAb,
and gated for B220 cells. Mean percentages of MZ B cells
(CD21highCD23neg/low) in spleen are indicated. Representative results from
four to five mice in each group are shown. B, Histograms show comparable
CD21 staining of follicular (CD21intCD23high) B cells between Yaa and
non-Yaa Sp6 transgenic male mice. Mean fluorescence intensity (SD) of
CD21 from five Sp6 transgenic male mice in each group is given. C, Spon-
taneous secretion of IgM in vitro after a 24-h incubation of splenic B cells
from 2-mo-old BXSB Sp6 transgenic male mice of the Yaa or non-Yaa
genotype was determined by ELISA. IgM concentrations in supernatants
from three different mice (means  SD) are expressed as nanograms per
milliliter of IgM.
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of preferential expansion of MZ B cells in aged BXSB Yaa males
developing severe SLE strongly argues against a major role of MZ
B cells in the generation of pathogenic autoantibodies in the BXSB
model of SLE.
Several recent studies have proposed a possible role for MZ B
cells in the spontaneous production of lupus autoantibodies in
mice. First, the size of the MZ B cell compartment has been re-
ported to be enlarged in lupus-prone (NZB  NZW)F1 mice (15),
and it was claimed to be linked to the Nba2 locus (41), which
provides the major contribution to lupus susceptibility in this
model of SLE (42). Second, CD1dhigh B cells, a phenotype of MZ
B cells, have been shown to produce more IgM autoantibodies than
follicular B cells in (NZB  NZW)F1 mice (14). Third, mice over-
expressing BAFF developed a lupus-like autoimmune syndrome in
parallel to an expansion of MZ B cells (16). Finally, low affinity
autoreactive B cells could be positively selected into the MZ (18,
19, 40). However, as shown in the present study, a specific reduc-
tion, rather than an expansion, of MZ B cells in aged BXSB Yaa
males developing a lethal form of SLE suggests that the MZ B
cells are not critically involved in the Yaa-mediated accelerated
development of SLE in these mice. However, our results cannot
totally exclude the possibility that low numbers of MZ B cells in
BXSB Yaa male mice may in part be due to an increased activation
of autoreactive B cells in the MZ and their exit from this com-
partment. In fact, it has been reported that MZ B cells undergo
rapid migration to lymphoid follicles after exposure to blood-borne
bacterial products (43). Clearly, the experiment in lupus-prone
mice genetically deficient in the MZ B cell compartment would
provide a more definite conclusion to this issue.
It has been shown that MZ B cells are capable of differentiating
into plasma cells very rapidly upon stimulation with polyclonal B
cell activators (10). It may be possible that MZ B cells bearing low
affinity self-reactive BCR produce so-called natural autoantibodies
of the IgM isotype upon contact with blood-borne pathogens. These
natural IgM autoantibodies could play an important role in self toler-
ance, possibly by promoting the elimination of pathogenic self Ags or
maintaining central tolerance through opsonization of self Ags with
complement (44), as shown in mice deficient in secretory IgM, which
are predisposed to the production of IgG autoantibodies (45, 46). If
this is the case, the loss of MZ B cells occurring in mice bearing the
Yaa mutation could rather promote autoimmune responses, because of
a limited production of beneficial natural IgM autoantibodies. This
could partially explain the increased production of IgG autoantibodies
in CD22/ or Lyn/ mice having decreased MZ B cell compart-
ments (47–49). Furthermore, it is worth mentioning that, in contrast to
recent findings based on linkage analysis in (B6  NZB)F2 mice (41),
the development of MZ B cells was substantially reduced in B6 mice
congenic for the Nba2 locus (unpublished data), which produce an-
tinuclear autoantibodies characteristic of SLE (42).
The mechanism by which the Yaa mutation affects the MZ B
cell development remains speculative, because the molecular de-
fect caused by the Yaa mutation has not yet been defined. Studies
in Aiolos/ mice, which are deficient in MZ B cells, revealed that
their B cells were more readily activated in response to BCR trig-
gering, and that the follicular B cells show hyperreactive pheno-
types (24). Therefore, it has been proposed that the strength of the
signal elicited via the BCR regulates the lineage commitment of
mature B cells into follicular vs MZ B cells, in which relatively
strong signals favor follicular B cell generation, while weaker sig-
nals induce differentiation into MZ B cells. This hypothesis is con-
sistent with the increased development of MZ B cells in Btk-de-
ficient mice, in which BCR signal strength is decreased (23, 24),
and the impaired MZ B cell generation in CD22/ mice, in which
BCR signaling is enhanced (26). Significantly, the present study
revealed that B cells bearing the Yaa mutation share the phenotype
of hyperreactive B cells, as shown by a decreased expression level
of CD21 and a markedly increased spontaneous production of IgM
Abs by splenic B cells in young B6 Yaa mice, which do not show
any sign of autoantibody production. In addition, it can be spec-
ulated that a pronounced decrease of T2 B cells in the Yaa mice,
as is the case in CD22/ and Aiolos/ mice (24), may be a
result of the accelerated and preferential differentiation of Yaa-
bearing T2 cells into follicular B cells. Thus, an attractive hypoth-
esis is that the Yaa mutation may act as a positive BCR regulator,
thereby modulating the maturation of MZ B cells. However, unlike
B cells deficient in Aiolos or CD22 (24), Yaa B cells did not show
an enhanced Ca2 release upon BCR stimulation by anti-IgM
mAb, although we cannot exclude the possibility that the effect of
the Yaa mutation on BCR signaling may be too subtle to be de-
tected under this experimental condition.
An alternative possibility is that a signal derived from surround-
ing cells may play an additional role in the activation, differenti-
ation, or survival of mature B cells in spleen, in which the Yaa
mutation is implicated, thereby affecting the development of MZ B
cells. It has been reported that the development of MZ B cells is
markedly reduced in CD19-deficient mice (23, 50), despite the fact
that CD19 functions as a positive BCR regulator through the for-
mation of the BCR coreceptor complex with CD21 (51). However,
because of the presence of CD19 in excess of CD21 on the cell
surface, it has been speculated that CD19 may act as a receptor for
unidentified ligands (51), thereby regulating the generation or sur-
vival of MZ B cells in a BCR-independent manner. In addition, we
have recently observed that mice deficient in CD40 or CD40 li-
gand have an increased proportion of MZ B cells (unpublished
data). Although the expression levels of CD19 and CD40 are not
altered in splenic B cells from Yaa mice, it might be worth inves-
tigating whether the Yaa mutation can modulate the CD19 or
CD40 signaling pathway.
It is also possible that the Yaa mutation leads to defects in the
motility and responsiveness to chemokines critical for the migra-
tion of MZ B precursors to the appropriate site. This hypothesis
has been used to explain the loss of MZ B cells in mice lacking
Pyk-2 tyrosine kinase, Lsc (the murine homologue of human p115
Rho GTP exchange factor), or DOCK-2 (a hemopoietic cell-spe-
cific CDM family protein) (20–22). In addition, a more recent
study has demonstrated a critical role of integrins, LFA-1 and
41, in the localization and retention of MZ B cells (37). How-
ever, the expression levels of these integrins on MZ and follicular
B cells in Yaa mice were not different from those in non-Yaa mice.
Furthermore, we observed that BXSB Yaa male mice expressing
the Sp6 anti-TNP/DNA transgene developed a MZ B cell com-
partment almost comparable to that of non-Yaa counterparts.
Therefore, we consider a migration defect to the MZ or a local-
ization and retention defect within the MZ as a less likely expla-
nation for the loss of MZ B cells in Yaa mice. In addition, the
experiment with the Sp6 transgenic mice further supports the de-
pendence on BCR specificity and signaling in maturation and sur-
vival of MZ B cells. The increase of MZ B cell compartment in the
Sp6 transgenic mice is consistent with the finding that low affinity
self-reactive B cells tend to be accumulated in the MZ (19, 40). It
has been speculated that self Ags may very weakly trigger such
autoreactive B cells, thereby favoring the differentiation into MZ B
cells (23, 24, 40). In this regard, it is of interest to note that the
follicular B cells bearing the Sp6 transgene and Yaa mutation no
longer showed hyperreactive phenotypes, consistent with the nor-
mal development of the MZ B cell compartment in the Sp6 trans-
genic Yaa mice. One possible explanation for this is that these
2299The Journal of Immunology












autoreactive B cells could become partially anergic, thus counter-
acting the action of the Yaa mutation. This possibility warrants
further investigation by using different Ig transgenic mice bearing
the Yaa mutation.
It is significant that follicular B cells in Yaa mice exhibit hy-
perreactive phenotypes, as judged by an increased spontaneous
secretion of IgM in vitro. This was further supported by serological
analysis, showing increased levels of serum IgM in 5- to 6-wk-old
young B6 and BXSB Yaa males, as compared with non-Yaa males
(unpublished data). This is in agreement with the earlier observa-
tion that spleen cells from BXSB Yaa males exhibit an increased
polyclonal IgM Ab production early in their life, as compared with
those from BXSB female mice (52). This would also explain why
Ab responses against TI-2 Ags were not diminished in the Yaa
mice (31), in contrast to lower Ab responses against TI-2 Ags in
several, but not all, mice deficient in the MZ B cell development
(13, 20, 26, 53). It has been reported that mice overexpressing
CD19 or deficient in CD22 or Lyn, in which B cells become ab-
normally hyperresponsive to antigenic stimulation, spontaneously
produced increased levels of autoantibodies (48, 49, 54, 55).
Therefore, it is reasonable to assume that the hyperreactive phe-
notype of Yaa B cells is implicated in the Yaa-mediated acceler-
ation of autoantibody production in lupus-prone mice.
In conclusion, we have shown in the present study that the Yaa
mutation causes an impaired development of MZ B cells, and that
the lack of selective expansion of MZ B cells in diseased BXSB
Yaa male mice argues against a critical role of MZ B cells in the
generation of pathogenic autoantibodies in this SLE model. It can
be hypothesized that in the presence of the Yaa mutation, B cells
may be more readily activated by putative natural in vivo ligand(s),
thereby contributing not only to the enhanced maturation into fol-
licular B cells and the block of MZ B cell generation, but also to
the accelerated development of SLE. The understanding of the
mechanism responsible for the Yaa-associated MZ B cell defect
and the hyperreactive phenotype of Yaa B cells is of paramount
importance for the elucidation of the molecular abnormality
caused by the Yaa mutation, and hence the development of lupus-
like systemic autoimmune disease.
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